Patents
Literature
2 results about "Reverse-transcriptase inhibitor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Reverse-transcriptase inhibitors (RTIs) are a class of antiretroviral drugs used to treat HIV infection or AIDS, and in some cases hepatitis B. RTIs inhibit activity of reverse transcriptase, a viral DNA polymerase that is required for replication of HIV and other retroviruses.
Crystal form of an HIV nucleoside reverse transcriptase inhibitor
PCT designated stageWO2026136102A1Organic active ingredientsSugar derivativesNucleoside Reverse Transcriptase InhibitorMedicine
This disclosure provides crystalline forms of a compound of Formula (A), and pharmaceutical compositions thereof. This disclosure further provides methods for their preparation and use in methods of treatment, prophylaxis, or delay in onset or progression of HIV infection or AIDS in a subject. This disclosure further provides dosage forms, such as oral tablets, of a compound of Formula (A) and its crystalline forms.
Owner:MERCK SHARP & DOHME LLC
Combination therapy for treating hepatitis b virus (HBV) infection
PCT designated stageWO2026107341A1Digestive systemAntibody ingredientsHepatitis B immunizationAntiendomysial antibodies
The present disclosure provides methods for treating HBV infection using combination therapies in patients with serum HBsAg levels below 3000 IU / mL prior to treatment. The components of the combination therapies may include one or more of an anti-HBV antibody; an siRNA that targets an HBV mRNA; interferon-α; and a nucleos(t)ide reverse transcriptase inhibitor (NRTI).
Owner:VIR BIOTECHNOLOGY INC